NCT01021358View on ClinicalTrials.gov

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

October 31, 2010

Conditions
LymphomaChronic Lymphocytic LeukemiaSolid Tumors
Interventions
DRUG

ABT-263

Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.

DRUG

Ketoconazole

Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.

Trial Locations (1)

78229

Site Reference ID/Investigator# 25068, San Antonio

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY